trial

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCTId NCT02087579
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 305 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2014-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
305 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-02
Primary completion
2014-10
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
AripiprazoleOlanzapinePaliperidoneQuetiapineRisperidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
305
Phase
PHASE1
Primary Completion Date
2014-10
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Olanzapine
drug
Paliperidone
drug
Quetiapine
drug
Risperidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Depressive Disorder
indication